key: cord-0850073-0nxxgwxl
authors: Lockey, Richard F.; Hudey, Stephanie N.
title: COVID-19 – associated urticaria with angioedema in a morbidly obese male successfully treated with glucocorticoids
date: 2020-07-22
journal: Ann Allergy Asthma Immunol
DOI: 10.1016/j.anai.2020.07.019
sha: c234a15ec0b06502e1aad07982500a8b85d41559
doc_id: 850073
cord_uid: 0nxxgwxl

nan

Onset of severe urticaria has been linked to viral infections in both children, and adults 1 . We 1 describe a morbidly obese male smoker patient with severe refractory urticaria, angioedema and 2 systemic symptoms requiring oral glucocorticoids who was subsequently diagnosed with 3 COVID-19 and had a successful outcome.Patient was 36-year-old obese male who presented 4 with a complaint of acute urticaria. He awoke (day 0) with generalized erythema and pruritus 5 and the gradual onset of generalized urticaria (palms and soles included). He was seen in an ED 6 and placed on a methylprednisolone dose pack and diphenhydramine 50 mg PO twice daily. On 7 day 6, he returned to the ED for a relapse of his symptoms and was continued on both prednisone 8 20 mg PO twice daily and diphenhydramine 50 mg PO twice daily and began cefdinir 500mg PO 9 four times daily. He awoke three days later ( day 9) with generalized erythema, pruritus, 10 urticaria and angioedema of his lips. When he arrived at the ED (within 20 minutes), he had 11 dyspnea , cough and wheezing. He was treated with nebulized albuterol, diphenhydramine, 12 epinephrine, famotidine, methylprednisolone IM, and IV saline. He responded and was 13 asymptomatic when dischareged from the ED. He continued both prednisone 20 mg PO and 14 diphenhydramine 50 mg PO, each twice daily and stopped cefdinir. 15 16 He was seen in our clinic on day 11 . He and could not relate his urticaria to time, place or action 17 but had developed anosmia and ageusia the day before this visit. He had no other symptoms. His 18 past medical, social, and family histories and review of systems were unremarkable except for a 19 15 pack-year smoking history (currently 2.5 packs/day). He had no history of asthma and works 20 as a door host at a bar. 21

Physical examination revealed an obese male (BMI 44) with normal vital signs and 22 unremarkable examination other than slight erythema of the nasal mucosal membranes and 23 scattered urticaria lesions on his torso. CBC, serum tryptase, and COVID-19 test were ordered. 24

He was prescribed prednisone 20 mg PO twice daily and high dose oral cetirizine. Instead, he 25 continued diphenhydramine 50 mg twice daily. Two days later (day 13) his COVID-19 test was 26 reported positive. CBC was normal except for WBC of 13,100 (3.8 -10.8 cells/µL) and absolute 27 neutrophil count of 9419 (1500-7800 cells/µL), which was attributed to glucocorticoids). Serum 28 tryptase was 5.9 (< 11 μg/L). He was morbidly obese and a heavy smoker, placing him at higher risk for severe COVID-19 3 . 42

He was immediately and continually treated with oral glucocorticoids. We speculate a cause and 43 effect relationship may have existed such that COVID-19 caused his severe urticaria and a 44 systemic "allergic" reaction including acute bronchospasm , the only time he had ever wheezed . 45

Cutaneous manifestations of COVID-19 are described in a cohort of 88 Italian subjects, 20% of 46 whom had cutaneous symptoms (3.4% had urticaria) but none as a presenting sign or symptom 4 . 47

There is also a report of urticaria with facial angioedema on day 11 of a mild case of COVID-19 48 whichresolved within 24 hours with high-dose antihistamine treatment. Glucocorticoids were not 49 required and the urticaria was not accompanied by any systemic signs or symptoms 5 . 

Association 2 between urticaria and virus infections: A systematic review

Systemic Complaints and Their Relationship with Disease and Immune Measures

Severe Covid-19

Cutaneous manifestations in COVID-19: a first perspective

Acute urticaria with 11 angioedema in the setting of coronavirus disease 2019

Role of corticosteroid in the management of 14

COVID-19: A systemic review and a Clinician's perspective

Effect of dexamethasone in 17 hospitalized patients with COVID-19 -preliminary report. medRxiv

Asthma Exacerbations: Pathogenesis, Prevention, and 19